ImmunoPrecise Antibodies Ltd. (IPA)
USD 0.46
(-0.71%)
USD 0.46
(-0.71%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -13.76 Million CAD | 47.34% |
| 2022 | -26.09 Million CAD | -65.33% |
| 2021 | -15.78 Million CAD | -137.2% |
| 2020 | -6.65 Million CAD | -62.51% |
| 2019 | -4.09 Million CAD | 34.25% |
| 2018 | -6.22 Million CAD | -26.33% |
| 2017 | -4.92 Million CAD | -255.52% |
| 2016 | -1.38 Million CAD | -671.4% |
| 2015 | 242.64 Thousand CAD | 752.05% |
| 2014 | -37.21 Thousand CAD | 61.85% |
| 2013 | -97.55 Thousand CAD | -19.97% |
| 2012 | -81.31 Thousand CAD | 60.9% |
| 2011 | -207.97 Thousand CAD | 21.49% |
| 2010 | -264.89 Thousand CAD | 10.14% |
| 2009 | -294.77 Thousand CAD | 26.84% |
| 2008 | -402.92 Thousand CAD | 67.07% |
| 2007 | -1.22 Million CAD | -193.72% |
| 2006 | -416.62 Thousand CAD | -4.24% |
| 2005 | -399.69 Thousand CAD | -98.64% |
| 2004 | -201.22 Thousand CAD | 68.67% |
| 2003 | -642.2 Thousand CAD | -307.08% |
| 2002 | -157.75 Thousand CAD | 32.25% |
| 2001 | -232.83 Thousand CAD | -56.71% |
| 2000 | -148.58 Thousand CAD | 87.92% |
| 1999 | -1.23 Million CAD | 1.57% |
| 1998 | -1.24 Million CAD | -237.68% |
| 1997 | -370.13 Thousand CAD | -67.02% |
| 1996 | -221.6 Thousand CAD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | -4.62 Million CAD | -169.57% |
| 2023 Q3 | -3.34 Million CAD | -19.54% |
| 2023 Q1 | -9.74 Million CAD | -169.57% |
| 2023 FY | -13.73 Million CAD | 47.34% |
| 2023 Q4 | -3.85 Million CAD | -15.33% |
| 2023 Q2 | -2.79 Million CAD | 71.33% |
| 2022 Q4 | -3.61 Million CAD | 20.0% |
| 2022 Q3 | -4.51 Million CAD | 41.87% |
| 2022 FY | -26.09 Million CAD | -65.33% |
| 2022 Q1 | -10.07 Million CAD | -203.37% |
| 2022 Q2 | -7.77 Million CAD | 22.82% |
| 2021 Q1 | -3.37 Million CAD | -36.71% |
| 2021 Q4 | -3.32 Million CAD | 22.92% |
| 2021 Q3 | -4.3 Million CAD | 8.13% |
| 2021 Q2 | -4.68 Million CAD | -38.9% |
| 2021 FY | -15.78 Million CAD | -137.2% |
| 2020 Q3 | -954.67 Thousand CAD | -44.56% |
| 2020 Q2 | -660.41 Thousand CAD | -615.86% |
| 2020 Q1 | -92.25 Thousand CAD | 93.35% |
| 2020 FY | -6.65 Million CAD | -62.51% |
| 2020 Q4 | -2.46 Million CAD | -158.59% |
| 2019 FY | -4.09 Million CAD | 34.25% |
| 2019 Q4 | -1.38 Million CAD | -602.46% |
| 2019 Q3 | -197.51 Thousand CAD | 80.09% |
| 2019 Q1 | -1.46 Million CAD | 57.02% |
| 2019 Q2 | -991.83 Thousand CAD | 32.52% |
| 2018 Q2 | -1.12 Million CAD | -29.68% |
| 2018 FY | -6.22 Million CAD | -26.33% |
| 2018 Q1 | -870.88 Thousand CAD | 54.17% |
| 2018 Q3 | -833.77 Thousand CAD | 26.17% |
| 2018 Q4 | -3.41 Million CAD | -310.17% |
| 2017 Q2 | -915.04 Thousand CAD | -6.67% |
| 2017 FY | -4.92 Million CAD | -255.52% |
| 2017 Q3 | -1.07 Million CAD | -17.94% |
| 2017 Q4 | -1.9 Million CAD | -76.08% |
| 2017 Q1 | -857.83 Thousand CAD | 21.21% |
| 2016 Q4 | -1.08 Million CAD | -85.15% |
| 2016 Q3 | -588.01 Thousand CAD | -588.28% |
| 2016 Q2 | 120.42 Thousand CAD | 0.0% |
| 2016 Q1 | 120.42 Thousand CAD | 2936.22% |
| 2016 FY | -1.38 Million CAD | -671.4% |
| 2015 FY | 242.64 Thousand CAD | 752.05% |
| 2015 Q1 | -5202.00 CAD | -291.6% |
| 2015 Q2 | -2940.00 CAD | 43.48% |
| 2015 Q3 | -15.17 Thousand CAD | -416.12% |
| 2015 Q4 | -4246.00 CAD | 72.02% |
| 2014 FY | -37.21 Thousand CAD | 61.85% |
| 2014 Q4 | 2715.00 CAD | -78.84% |
| 2014 Q3 | 12.83 Thousand CAD | 143.76% |
| 2014 Q2 | -29.32 Thousand CAD | -1452.51% |
| 2014 Q1 | -1889.00 CAD | 89.97% |
| 2013 FY | -97.55 Thousand CAD | -19.97% |
| 2013 Q4 | -18.83 Thousand CAD | 58.91% |
| 2013 Q3 | -45.82 Thousand CAD | -112.63% |
| 2013 Q2 | -21.55 Thousand CAD | -72.84% |
| 2013 Q1 | -12.46 Thousand CAD | 29.6% |
| 2012 Q4 | -17.71 Thousand CAD | 48.95% |
| 2012 Q2 | -18.3 Thousand CAD | -184.45% |
| 2012 Q1 | -6436.00 CAD | 70.59% |
| 2012 FY | -81.31 Thousand CAD | 60.9% |
| 2012 Q3 | -34.69 Thousand CAD | -89.5% |
| 2011 Q3 | -46.14 Thousand CAD | 27.07% |
| 2011 FY | -207.97 Thousand CAD | 21.49% |
| 2011 Q4 | -21.88 Thousand CAD | 52.58% |
| 2011 Q2 | -63.26 Thousand CAD | -3.84% |
| 2011 Q1 | -60.92 Thousand CAD | -61.84% |
| 2010 Q2 | -50.63 Thousand CAD | -0.88% |
| 2010 Q4 | -37.64 Thousand CAD | 63.02% |
| 2010 Q3 | -101.78 Thousand CAD | -101.04% |
| 2010 Q1 | -50.18 Thousand CAD | 19.42% |
| 2010 FY | -264.89 Thousand CAD | 10.14% |
| 2009 Q1 | -46.36 Thousand CAD | 28.72% |
| 2009 FY | -294.77 Thousand CAD | 26.84% |
| 2009 Q3 | -129.06 Thousand CAD | -137.73% |
| 2009 Q2 | -54.29 Thousand CAD | -17.09% |
| 2009 Q4 | -62.28 Thousand CAD | 51.74% |
| 2008 Q4 | -65.05 Thousand CAD | 81.85% |
| 2008 Q2 | 71 Thousand CAD | 232.71% |
| 2008 Q1 | -53.5 Thousand CAD | 13.82% |
| 2008 FY | -402.92 Thousand CAD | 67.07% |
| 2008 Q3 | -358.34 Thousand CAD | -604.64% |
| 2007 Q3 | -632.71 Thousand CAD | -2592.17% |
| 2007 Q4 | -62.08 Thousand CAD | 90.19% |
| 2007 Q2 | -23.5 Thousand CAD | 95.43% |
| 2007 Q1 | -514.24 Thousand CAD | -799.58% |
| 2007 FY | -1.22 Million CAD | -193.72% |
| 2006 Q1 | -237.27 Thousand CAD | -305.46% |
| 2006 Q2 | -39 Thousand CAD | 83.56% |
| 2006 FY | -416.62 Thousand CAD | -4.24% |
| 2006 Q4 | -57.16 Thousand CAD | 25.6% |
| 2006 Q3 | -76.83 Thousand CAD | -97.0% |
| 2005 Q4 | -58.52 Thousand CAD | 13.73% |
| 2005 FY | -399.69 Thousand CAD | -98.64% |
| 2005 Q2 | -213.11 Thousand CAD | -370.24% |
| 2005 Q3 | -67.83 Thousand CAD | 68.17% |
| 2005 Q1 | -45.31 Thousand CAD | 38.29% |
| 2004 Q2 | -19.33 Thousand CAD | 51.47% |
| 2004 Q4 | -73.43 Thousand CAD | 14.96% |
| 2004 Q3 | -86.35 Thousand CAD | -346.68% |
| 2004 Q1 | -39.84 Thousand CAD | 29.91% |
| 2004 FY | -201.22 Thousand CAD | 68.67% |
| 2003 FY | -642.2 Thousand CAD | -307.08% |
| 2003 Q4 | -56.84 Thousand CAD | 89.2% |
| 2003 Q2 | -28.82 Thousand CAD | 40.6% |
| 2003 Q3 | -526.51 Thousand CAD | -1726.86% |
| 2003 Q1 | -48.51 Thousand CAD | -25.07% |
| 2002 Q2 | -32.12 Thousand CAD | 39.38% |
| 2002 FY | -157.75 Thousand CAD | 32.25% |
| 2002 Q4 | -38.79 Thousand CAD | -17.02% |
| 2002 Q1 | -52.98 Thousand CAD | -34.0% |
| 2002 Q3 | -33.15 Thousand CAD | -3.21% |
| 2001 Q4 | -39.54 Thousand CAD | -5.34% |
| 2001 FY | -232.83 Thousand CAD | -56.71% |
| 2001 Q3 | -37.53 Thousand CAD | 55.0% |
| 2001 Q2 | -83.41 Thousand CAD | 25.36% |
| 2001 Q1 | -111.75 Thousand CAD | -183.78% |
| 2000 Q3 | -41.82 Thousand CAD | -25.97% |
| 2000 Q2 | -33.2 Thousand CAD | 13.1% |
| 2000 Q1 | -38.2 Thousand CAD | -8.08% |
| 2000 FY | -148.58 Thousand CAD | 87.92% |
| 2000 Q4 | -39.38 Thousand CAD | 5.84% |
| 1999 Q1 | -53.63 Thousand CAD | -0.06% |
| 1999 Q2 | -38.63 Thousand CAD | 27.97% |
| 1999 FY | -1.23 Million CAD | 1.57% |
| 1999 Q3 | -1.21 Million CAD | -3044.49% |
| 1999 Q4 | -35.35 Thousand CAD | 97.09% |
| 1998 Q4 | -53.6 Thousand CAD | 95.08% |
| 1998 FY | -1.24 Million CAD | -237.68% |
| 1998 Q1 | -62.67 Thousand CAD | -27.47% |
| 1998 Q2 | -48.42 Thousand CAD | 22.73% |
| 1998 Q3 | -1.08 Million CAD | -2150.08% |
| 1997 Q4 | -49.16 Thousand CAD | 69.9% |
| 1997 Q1 | -110.16 Thousand CAD | -142.79% |
| 1997 Q2 | -51.26 Thousand CAD | 53.47% |
| 1997 FY | -370.13 Thousand CAD | -67.02% |
| 1997 Q3 | -163.33 Thousand CAD | -218.6% |
| 1996 Q4 | -45.37 Thousand CAD | 0.0% |
| 1996 FY | -221.6 Thousand CAD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Absci Corporation | -115.51 Million USD | 88.086% |
| Adaptive Biotechnologies Corporation | -227.03 Million USD | 93.938% |
| Alnylam Pharmaceuticals, Inc. | -282.17 Million USD | 95.123% |
| Alzamend Neuro, Inc. | -9.93 Million USD | -38.484% |
| Apollomics, Inc. | -54.83 Million USD | 74.902% |
| 180 Life Sciences Corp. | -13.47 Million USD | -2.111% |
| Atossa Therapeutics, Inc. | -31.37 Million USD | 56.14% |
| Bicycle Therapeutics plc | -189.94 Million USD | 92.755% |
| Barinthus Biotherapeutics plc | -83.91 Million USD | 83.6% |
| BioXcel Therapeutics, Inc. | -171.78 Million USD | 91.989% |
| CASI Pharmaceuticals, Inc. | -25.28 Million USD | 45.562% |
| Chimerix, Inc. | -93.06 Million USD | 85.212% |
| CRISPR Therapeutics AG | -222.53 Million USD | 93.816% |
| Contineum Therapeutics, Inc. Class A Common Stock | 16.07 Million USD | 185.601% |
| EyePoint Pharmaceuticals, Inc. | -73.66 Million USD | 81.317% |
| Fortress Biotech, Inc. | -142.34 Million USD | 90.332% |
| Fortress Biotech, Inc. | -142.34 Million USD | 90.332% |
| Gritstone bio, Inc. | -154.63 Million USD | 91.1% |
| Allakos Inc. | -196.05 Million USD | 92.981% |
| Boundless Bio, Inc. Common Stock | -54.79 Million USD | 74.885% |
| Cara Therapeutics, Inc. | -121.49 Million USD | 88.673% |
| Cytokinetics, Incorporated | -496.2 Million USD | 97.227% |
| enGene Holdings Inc. Common Stock | -26.06 Million USD | 47.191% |
| Innoviva, Inc. | 176.7 Million USD | 107.788% |
| Hoth Therapeutics, Inc. | -7.69 Million USD | -78.908% |
| NLS Pharmaceutics AG | -11.8 Million USD | -16.557% |
| RAPT Therapeutics, Inc. | -127.06 Million USD | 89.169% |
| Salarius Pharmaceuticals, Inc. | -12.89 Thousand USD | -106624.033% |
| Terns Pharmaceuticals, Inc. | -102.55 Million USD | 86.581% |
| Vigil Neuroscience, Inc. | -88.86 Million USD | 84.514% |
| ImmuCell Corporation | -5.74 Million USD | -139.419% |
| IDEAYA Biosciences, Inc. | -134.42 Million USD | 89.763% |
| Incyte Corporation | 620.52 Million USD | 102.218% |
| Inovio Pharmaceuticals, Inc. | -135.22 Million USD | 89.823% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -110.621% |
| Mustang Bio, Inc. | -50.72 Million USD | 72.87% |
| MiMedx Group, Inc. | 37.11 Million USD | 137.078% |
| MEI Pharma, Inc. | 14.54 Million USD | 194.636% |
| MacroGenics, Inc. | -168.24 Million USD | 91.82% |
| Monopar Therapeutics Inc. | -8.83 Million USD | -55.833% |
| Mereo BioPharma Group plc | -28.41 Million USD | 51.57% |
| Marker Therapeutics, Inc. | -14.58 Million USD | 5.619% |
| Marinus Pharmaceuticals, Inc. | -131.48 Million USD | 89.533% |
| Maravai LifeSciences Holdings, Inc. | -31.64 Million USD | 56.515% |
| Minerva Neurosciences, Inc. | -23.11 Million USD | 40.475% |
| NeuroBo Pharmaceuticals, Inc. | -15.88 Million USD | 13.37% |
| NeuroSense Therapeutics Ltd. | -12.04 Million USD | -14.217% |
| NextCure, Inc. | -67.63 Million USD | 79.653% |
| Orchestra BioMed Holdings, Inc. | -51.5 Million USD | 73.281% |
| Ocuphire Pharma, Inc. | -10.56 Million USD | -30.285% |
| Onconetix, Inc. | -36.03 Million USD | 61.809% |
| Oncternal Therapeutics, Inc. | -41.71 Million USD | 67.009% |
| Opthea Limited | -191.84 Million USD | 92.826% |
| Ovid Therapeutics Inc. | -59.28 Million USD | 76.785% |
| Psyence Biomedical Ltd. | -2.75 Million USD | -400.104% |
| PDS Biotechnology Corporation | -43.04 Million USD | 68.029% |
| Precigen, Inc. | -88.92 Million USD | 84.524% |
| Pieris Pharmaceuticals, Inc. | -29.75 Million USD | 53.751% |
| Prime Medicine, Inc. | -191.29 Million USD | 92.806% |
| PureTech Health plc | -146.19 Million USD | 90.587% |
| Rocket Pharmaceuticals, Inc. | -259.65 Million USD | 94.7% |
| Regeneron Pharmaceuticals, Inc. | 4.04 Billion USD | 100.34% |
| Replimune Group, Inc. | -234.77 Million USD | 94.138% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -58.976% |
| Rigel Pharmaceuticals, Inc. | -20.49 Million USD | 32.839% |
| TransCode Therapeutics, Inc. | -19.41 Million USD | 29.129% |
| Revolution Medicines, Inc. Warrant | -487.18 Million USD | 97.175% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 43.382% |
| Sesen Bio, Inc. | -25.9 Million USD | 46.883% |
| Sangamo Therapeutics, Inc. | -274 Million USD | 94.977% |
| Solid Biosciences Inc. | -104.31 Million USD | 86.807% |
| Syndax Pharmaceuticals, Inc. | -229.95 Million USD | 94.015% |
| SciSparc Ltd. | -5.77 Million USD | -138.386% |
| Sutro Biopharma, Inc. | -89.27 Million USD | 84.585% |
| TG Therapeutics, Inc. | 20.63 Million USD | 166.699% |
| Tonix Pharmaceuticals Holding Corp. | -118.38 Million USD | 88.375% |
| Titan Pharmaceuticals, Inc. | -7.27 Million USD | -89.116% |
| Travere Therapeutics, Inc. | -376.74 Million USD | 96.347% |
| UroGen Pharma Ltd. | -65.53 Million USD | 79.001% |
| Verrica Pharmaceuticals Inc. | -65.75 Million USD | 79.072% |
| XOMA Corporation | -41.84 Million USD | 67.114% |
| Zentalis Pharmaceuticals, Inc. | -248.98 Million USD | 94.473% |
| AbCellera Biologics Inc. | -237.2 Million USD | 94.198% |
| Longboard Pharmaceuticals, Inc. | -56.75 Million USD | 75.754% |
| Cassava Sciences, Inc. | -105.95 Million USD | 87.012% |
| Corbus Pharmaceuticals Holdings, Inc. | -45.07 Million USD | 69.47% |
| Precision BioSciences, Inc. | -43.73 Million USD | 68.534% |
| Dyadic International, Inc. | -8.22 Million USD | -67.223% |
| Intensity Therapeutics, Inc. | -8.31 Million USD | -65.429% |
| Eton Pharmaceuticals, Inc. | -1.19 Million USD | -1054.53% |
| VYNE Therapeutics Inc. | -29.25 Million USD | 52.963% |
| Tenaya Therapeutics, Inc. | -131.19 Million USD | 89.51% |
| IGM Biosciences, Inc. | -263.46 Million USD | 94.776% |
| X4 Pharmaceuticals, Inc. | -107.52 Million USD | 87.201% |
| Acelyrin, Inc. | -422.06 Million USD | 96.739% |
| Abeona Therapeutics Inc. | -47.13 Million USD | 70.803% |
| Ligand Pharmaceuticals Incorporated | 11.94 Million USD | 215.24% |
| Inhibikase Therapeutics, Inc. | -20.08 Million USD | 31.498% |
| Arcturus Therapeutics Holdings Inc. | -78.2 Million USD | 82.403% |
| Syros Pharmaceuticals, Inc. | -128.98 Million USD | 89.331% |
| Senti Biosciences, Inc. | -92.72 Million USD | 85.159% |
| Mesoblast Limited | -58.79 Million USD | 76.593% |
| Kymera Therapeutics, Inc. | -165.53 Million USD | 91.686% |
| ChromaDex Corporation | -5.59 Million USD | -145.794% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -187.219% |
| Akebia Therapeutics, Inc. | -46.25 Million USD | 70.248% |
| Dermata Therapeutics, Inc. | -8.04 Million USD | -71.129% |
| Seer, Inc. | -103.46 Million USD | 86.699% |
| Xeris Biopharma Holdings, Inc. | -44.01 Million USD | 68.73% |
| Novavax, Inc. | -566.51 Million USD | 97.571% |
| Virpax Pharmaceuticals, Inc. | -15.68 Million USD | 12.287% |
| Fate Therapeutics, Inc. | -190.51 Million USD | 92.776% |
| Checkpoint Therapeutics, Inc. | -52.14 Million USD | 73.61% |
| Lyell Immunopharma, Inc. | -245.49 Million USD | 94.394% |
| Celcuity Inc. | -66.23 Million USD | 79.221% |
| ContextLogic Inc. | -328 Million USD | 95.804% |
| Phathom Pharmaceuticals, Inc. | -167.31 Million USD | 91.775% |
| HOOKIPA Pharma Inc. | -97.69 Million USD | 85.913% |
| Jazz Pharmaceuticals plc | 578.58 Million USD | 102.379% |
| Amarin Corporation plc | -67.58 Million USD | 79.638% |
| AnaptysBio, Inc. | -164.41 Million USD | 91.63% |
| Aptevo Therapeutics Inc. | -28.87 Million USD | 52.344% |
| Aptorum Group Limited | -10.52 Million USD | -30.776% |
| Cartesian Therapeutics, Inc. | -86.41 Million USD | 84.075% |
| Arrowhead Pharmaceuticals, Inc. | -205 Million USD | 93.287% |
| Ardelyx, Inc. | -63.27 Million USD | 78.251% |
| Celularity Inc. | -192.28 Million USD | 92.843% |
| Omeros Corporation | -164.53 Million USD | 91.636% |
| Humacyte, Inc. | -100.04 Million USD | 86.244% |
| Immunocore Holdings plc | -59.64 Million USD | 76.928% |
| IO Biotech, Inc. | -91.44 Million USD | 84.95% |
| GT Biopharma, Inc. | -13.57 Million USD | -1.37% |
| Cabaletta Bio, Inc. | -74.66 Million USD | 81.567% |
| Summit Therapeutics Inc. | -89.73 Million USD | 84.664% |
| Alaunos Therapeutics, Inc. | -34.26 Million USD | 59.839% |
| Pulmatrix, Inc. | -14.74 Million USD | 6.635% |
| Intellia Therapeutics, Inc. | -515.29 Million USD | 97.329% |
| Evogene Ltd. | -26.39 Million USD | 47.853% |
| CorMedix Inc. | -48.95 Million USD | 71.89% |
| BioLineRx Ltd. | -49.69 Million USD | 72.307% |
| VistaGen Therapeutics, Inc. | -33.02 Million USD | 58.323% |
| Sagimet Biosciences Inc. | -30.74 Million USD | 55.231% |
| PTC Therapeutics, Inc. | -349.4 Million USD | 96.061% |
| scPharmaceuticals Inc. | -55.39 Million USD | 75.157% |
| Fulcrum Therapeutics, Inc. | -110.66 Million USD | 87.564% |
| Corcept Therapeutics Incorporated | 107.28 Million USD | 112.828% |
| NLS Pharmaceutics AG | -11.8 Million USD | -16.557% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.3 Million USD | 43.382% |
| Akero Therapeutics, Inc. | -172.87 Million USD | 92.039% |
| Eliem Therapeutics, Inc. | -21.46 Million USD | 35.889% |
| Lisata Therapeutics, Inc. | -25.7 Million USD | 46.468% |
| Stoke Therapeutics, Inc. | -114.77 Million USD | 88.009% |
| Reneo Pharmaceuticals, Inc. | -83.05 Million USD | 83.43% |
| Outlook Therapeutics, Inc. | -53.12 Million USD | 74.096% |
| ProMIS Neurosciences, Inc. | -18.89 Million USD | 27.176% |
| Daré Bioscience, Inc. | -30.83 Million USD | 55.376% |
| bluebird bio, Inc. | -244.26 Million USD | 94.366% |
| BioMarin Pharmaceutical Inc. | 194.44 Million USD | 107.078% |
| DBV Technologies S.A. | -76.43 Million USD | 81.994% |
| Avidity Biosciences, Inc. | -235.59 Million USD | 94.159% |
| Galecto, Inc. | -39.9 Million USD | 65.513% |
| Sensei Biotherapeutics, Inc. | -37.06 Million USD | 62.87% |
| Spruce Biosciences, Inc. | -51.99 Million USD | 73.531% |
| Inhibrx Biosciences, Inc. | -219.22 Million USD | 93.722% |
| GlycoMimetics, Inc. | -39.27 Million USD | 64.96% |
| Arcutis Biotherapeutics, Inc. | -241.1 Million USD | 94.292% |
| ADMA Biologics, Inc. | 21.63 Million USD | 163.619% |
| Clene Inc. | -40.54 Million USD | 66.053% |
| Recursion Pharmaceuticals, Inc. | -350.06 Million USD | 96.069% |
| Aptose Biosciences Inc. | -52.35 Million USD | 73.715% |
| ZyVersa Therapeutics, Inc. | -14.42 Million USD | 4.568% |
| Soligenix, Inc. | -7.69 Million USD | -78.775% |
| Century Therapeutics, Inc. | -146.54 Million USD | 90.609% |
| Kura Oncology, Inc. | -165.8 Million USD | 91.7% |
| Surrozen, Inc. | -45.78 Million USD | 69.939% |
| TScan Therapeutics, Inc. | -93.45 Million USD | 85.275% |
| Ocean Biomedical, Inc. | -2.48 Million USD | -454.553% |
| CytomX Therapeutics, Inc. | -6.48 Million USD | -112.246% |
| Autolus Therapeutics plc | -195.02 Million USD | 92.944% |
| Mineralys Therapeutics, Inc. | -84.65 Million USD | 83.744% |
| Eterna Therapeutics Inc. | -21.13 Million USD | 34.885% |
| Caribou Biosciences, Inc. | -116.05 Million USD | 88.142% |
| GRI Bio, Inc. | -11.38 Million USD | -20.857% |
| Xenetic Biosciences, Inc. | -4.51 Million USD | -204.758% |
| Janux Therapeutics, Inc. | -72.97 Million USD | 81.143% |
| INmune Bio, Inc. | -29.74 Million USD | 53.727% |
| Heron Therapeutics, Inc. | -110.61 Million USD | 87.559% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 63.856% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 13.876% |
| Tenax Therapeutics, Inc. | -8.23 Million USD | -67.137% |
| Jaguar Health, Inc. | -34.29 Million USD | 59.867% |
| Entero Therapeutics, Inc. | -15.77 Million USD | 12.738% |
| Milestone Pharmaceuticals Inc. | -61.09 Million USD | 77.476% |
| Clearside Biomedical, Inc. | -24.84 Million USD | 44.606% |
| Atara Biotherapeutics, Inc. | -276 Million USD | 95.014% |
| Coherus BioSciences, Inc. | -203.19 Million USD | 93.227% |
| Verastem, Inc. | -92.08 Million USD | 85.055% |
| Pliant Therapeutics, Inc. | -184.14 Million USD | 92.527% |
| Histogen Inc. | -10.64 Million USD | -29.306% |
| Aprea Therapeutics, Inc. | -15.47 Million USD | 11.052% |
| ACADIA Pharmaceuticals Inc. | -73.37 Million USD | 81.245% |
| Surrozen, Inc. | -45.78 Million USD | 69.939% |
| Organovo Holdings, Inc. | -15.08 Million USD | 8.776% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -170.361% |
| Cadrenal Therapeutics, Inc. Common Stock | -7.63 Million USD | -80.3% |
| Centessa Pharmaceuticals plc | -171.28 Million USD | 91.965% |
| Hepion Pharmaceuticals, Inc. | -48.44 Million USD | 71.594% |
| BioRestorative Therapies, Inc. | -15.22 Million USD | 9.584% |
| Kronos Bio, Inc. | -121.83 Million USD | 88.704% |
| Turnstone Biologics Corp. | -59.03 Million USD | 76.687% |
| Synaptogenix, Inc. | -8.31 Million USD | -65.531% |
| Tiziana Life Sciences Ltd | -14.58 Million USD | 5.649% |
| Entrada Therapeutics, Inc. | -3.16 Million USD | -335.231% |
| Aurinia Pharmaceuticals Inc. | -91.69 Million USD | 84.991% |
| Exelixis, Inc. | 170.88 Million USD | 108.053% |
| Nurix Therapeutics, Inc. | -155.06 Million USD | 91.125% |
| Apellis Pharmaceuticals, Inc. | -517.12 Million USD | 97.339% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 80.015% |
| ESSA Pharma Inc. | -32.13 Million USD | 57.173% |
| TNF Pharmaceuticals, Inc. | -17.12 Million USD | 19.629% |
| Avid Bioservices, Inc. | -18.67 Million USD | 26.32% |
| Insmed Incorporated | -709.62 Million USD | 98.061% |
| MediWound Ltd. | -15.29 Million USD | 9.993% |
| OmniAb, Inc. | -69.41 Million USD | 80.175% |
| Alector, Inc. | -151.74 Million USD | 90.931% |
| Seres Therapeutics, Inc. | -107.98 Million USD | 87.255% |
| Zai Lab Limited | -366.57 Million USD | 96.246% |
| AlloVir, Inc. | -181.33 Million USD | 92.411% |
| Revance Therapeutics, Inc. | -316.77 Million USD | 95.656% |
| ORIC Pharmaceuticals, Inc. | -110.78 Million USD | 87.577% |
| Aura Biosciences, Inc. | -84.99 Million USD | 83.808% |
| Immunic, Inc. | -99.22 Million USD | 86.13% |
| Tarsus Pharmaceuticals, Inc. | -143.15 Million USD | 90.387% |
| Veracyte, Inc. | -85.79 Million USD | 83.959% |
| InMed Pharmaceuticals Inc. | - USD | Infinity% |
| FibroGen, Inc. | -281.81 Million USD | 95.117% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 3.153% |
| Catalyst Pharmaceuticals, Inc. | 86.81 Million USD | 115.853% |
| Adial Pharmaceuticals, Inc. | -6.88 Million USD | -99.798% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.79 Million USD | 26.769% |
| Cyclacel Pharmaceuticals, Inc. | -25.45 Million USD | 45.932% |
| Amylyx Pharmaceuticals, Inc. | 38.8 Million USD | 135.467% |
| Fortrea Holdings Inc. | 63.1 Million USD | 121.81% |
| KalVista Pharmaceuticals, Inc. | -140.44 Million USD | 90.201% |
| XBiotech Inc. | -37.51 Million USD | 63.311% |
| Jasper Therapeutics, Inc. | -68.86 Million USD | 80.015% |
| Keros Therapeutics, Inc. | -169.94 Million USD | 91.902% |
| SELLAS Life Sciences Group, Inc. | -37.86 Million USD | 63.659% |
| Lyra Therapeutics, Inc. | -67.12 Million USD | 79.496% |
| Foghorn Therapeutics Inc. | -107.9 Million USD | 87.246% |
| Agenus Inc. | -159.54 Million USD | 91.374% |
| Y-mAbs Therapeutics, Inc. | -25.67 Million USD | 46.393% |
| Theravance Biopharma, Inc. | -53.29 Million USD | 74.176% |
| Ultragenyx Pharmaceutical Inc. | -569.2 Million USD | 97.582% |
| Metagenomi, Inc. Common Stock | -78.49 Million USD | 82.467% |
| BioCryst Pharmaceuticals, Inc. | -103.7 Million USD | 86.73% |
| Gain Therapeutics, Inc. | -22.25 Million USD | 38.157% |
| C4 Therapeutics, Inc. | -139.03 Million USD | 90.101% |
| Creative Medical Technology Holdings, Inc. | -5.62 Million USD | -144.87% |
| Chemomab Therapeutics Ltd. | -25.45 Million USD | 45.944% |
| Lantern Pharma Inc. | -17.87 Million USD | 23.021% |
| Eledon Pharmaceuticals, Inc. | -43 Million USD | 67.995% |
| Ainos, Inc. | -13.2 Million USD | -4.207% |
| Pluri Inc. | -22.15 Million USD | 37.892% |
| Prothena Corporation plc | -191.03 Million USD | 92.796% |
| Adaptimmune Therapeutics plc | -138.03 Million USD | 90.03% |
| Rallybio Corporation | -78.93 Million USD | 82.565% |
| Kodiak Sciences Inc. | -277.32 Million USD | 95.038% |
| Cue Biopharma, Inc. | -52.14 Million USD | 73.61% |
| MeiraGTx Holdings plc | -137.06 Million USD | 89.959% |
| Annexon, Inc. | -143.72 Million USD | 90.425% |
| Assembly Biosciences, Inc. | -64.64 Million USD | 78.712% |
| Moderna, Inc. | -4.23 Billion USD | 99.675% |
| Cocrystal Pharma, Inc. | -18.55 Million USD | 25.847% |
| Cidara Therapeutics, Inc. | -24.48 Million USD | 43.79% |
| Blueprint Medicines Corporation | -486.27 Million USD | 97.17% |
| Immix Biopharma, Inc. | -16.14 Million USD | 14.739% |
| CalciMedica, Inc. | -21.87 Million USD | 37.088% |
| Monte Rosa Therapeutics, Inc. | -143.31 Million USD | 90.397% |
| Scholar Rock Holding Corporation | -171.29 Million USD | 91.966% |
| Wave Life Sciences Ltd. | -67.99 Million USD | 79.761% |
| Sana Biotechnology, Inc. | -326.9 Million USD | 95.79% |
| Elicio Therapeutics, Inc. | -35.74 Million USD | 61.5% |
| Adlai Nortye Ltd. American Depositary Shares | -67.55 Million USD | 79.627% |
| Nutriband Inc. | -4.87 Million USD | -182.476% |
| Protara Therapeutics, Inc. | -43.61 Million USD | 68.445% |
| Vor Biopharma Inc. | -126.03 Million USD | 89.081% |
| Roivant Sciences Ltd. | 4.24 Billion USD | 100.324% |
| Alkermes plc | 414.12 Million USD | 103.323% |
| ProKidney Corp. | -151.52 Million USD | 90.917% |
| Applied Therapeutics, Inc. | -64.53 Million USD | 78.675% |
| Arcellx, Inc. | -89.88 Million USD | 84.688% |
| BridgeBio Pharma, Inc. | -607.37 Million USD | 97.734% |
| Tango Therapeutics, Inc. | -114.17 Million USD | 87.946% |
| Galectin Therapeutics Inc. | -38.07 Million USD | 63.853% |
| Atai Life Sciences N.V. | -125.47 Million USD | 89.032% |
| Renovaro Biosciences Inc. | -81.63 Million USD | 83.143% |
| Aerovate Therapeutics, Inc. | -81.4 Million USD | 83.095% |
| MediciNova, Inc. | -9.9 Million USD | -39.006% |
| Praxis Precision Medicines, Inc. | -126.37 Million USD | 89.11% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -90.018% |
| GeoVax Labs, Inc. | -26.74 Million USD | 48.54% |
| Axsome Therapeutics, Inc. | -231.82 Million USD | 94.064% |
| Biomea Fusion, Inc. | -126.13 Million USD | 89.089% |
| RenovoRx, Inc. | -11.39 Million USD | -20.762% |
| Cullinan Oncology, Inc. | -191.08 Million USD | 92.798% |
| Geron Corporation | -193.94 Million USD | 92.904% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 50.114% |
| 4D Molecular Therapeutics, Inc. | -112.86 Million USD | 87.807% |
| Dyne Therapeutics, Inc. | -242.16 Million USD | 94.317% |
| Kiniksa Pharmaceuticals, Ltd. | -25.19 Million USD | 45.38% |
| Royalty Pharma plc | 1.49 Billion USD | 100.922% |
| Ventyx Biosciences, Inc. | -207.99 Million USD | 93.383% |
| Imunon, Inc. | -21.03 Million USD | 34.561% |
| BioAtla, Inc. | -129.68 Million USD | 89.388% |
| Allogene Therapeutics, Inc. | -327.73 Million USD | 95.801% |
| Larimar Therapeutics, Inc. | -41.75 Million USD | 67.043% |
| Mersana Therapeutics, Inc. | -170.95 Million USD | 91.95% |
| Structure Therapeutics Inc. | -102.77 Million USD | 86.61% |
| 89bio, Inc. | -151.2 Million USD | 90.898% |
| Kezar Life Sciences, Inc. | -105.23 Million USD | 86.923% |
| aTyr Pharma, Inc. | -54.91 Million USD | 74.941% |
| Aligos Therapeutics, Inc. | -87.42 Million USD | 84.259% |
| Viridian Therapeutics, Inc. | -254.45 Million USD | 94.591% |
| EyeGate Pharmaceuticals, Inc. | -8.21 Million USD | -67.569% |
| Akari Therapeutics, Plc | -16.8 Million USD | 18.113% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -155525.391% |
| Halozyme Therapeutics, Inc. | 337.57 Million USD | 104.077% |
| Lexicon Pharmaceuticals, Inc. | -171.75 Million USD | 91.987% |
| Liquidia Corporation | -73.38 Million USD | 81.247% |
| Entera Bio Ltd. | -8.89 Million USD | -54.786% |
| GH Research PLC | -41.22 Million USD | 66.615% |
| Vericel Corporation | -6.46 Million USD | -112.902% |
| Arbutus Biopharma Corporation | -78.1 Million USD | 82.38% |
| Xencor, Inc. | -138.63 Million USD | 90.074% |
| 60 Degrees Pharmaceuticals, Inc. | -5.15 Million USD | -166.986% |
| Pasithea Therapeutics Corp. | -15.97 Million USD | 13.876% |
| Coeptis Therapeutics Holdings, Inc. | -21.49 Million USD | 35.964% |
| Vaxcyte, Inc. | -468.04 Million USD | 97.06% |
| Xenon Pharmaceuticals Inc. | -214.05 Million USD | 93.571% |
| Vanda Pharmaceuticals Inc. | -13.95 Million USD | 1.362% |
| Lexaria Bioscience Corp. | -6.53 Million USD | -110.621% |
| Portage Biotech Inc. | -18.25 Million USD | 24.604% |
| Cardio Diagnostics Holdings, Inc. | -7.24 Million USD | -90.018% |
| Olema Pharmaceuticals, Inc. | -104.96 Million USD | 86.888% |
| OncoCyte Corporation | -25.13 Million USD | 45.25% |
| Qualigen Therapeutics, Inc. | -11.3 Million USD | -21.735% |
| Processa Pharmaceuticals, Inc. | -11.45 Million USD | -20.118% |
| Purple Biotech Ltd. | 22.27 Million USD | 161.793% |
| Tempest Therapeutics, Inc. | -29.15 Million USD | 52.8% |
| Sol-Gel Technologies Ltd. | -29.3 Million USD | 53.039% |
| Rhythm Pharmaceuticals, Inc. | -184.35 Million USD | 92.535% |
| CollPlant Biotechnologies Ltd. | -7.51 Million USD | -83.2% |
| Moleculin Biotech, Inc. | -29.63 Million USD | 53.555% |
| United Therapeutics Corporation | 1.18 Billion USD | 101.161% |
| HilleVax, Inc. | -133.34 Million USD | 89.679% |
| Silo Pharma, Inc. | -3.85 Million USD | -256.936% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | -249.108% |
| Pharming Group N.V. | -4.87 Million USD | -182.035% |
| Tharimmune, Inc. | -9.45 Million USD | -45.549% |
| Genprex, Inc. | -31.07 Million USD | 55.714% |
| Apogee Therapeutics, Inc. | -93 Million USD | 85.203% |
| Neumora Therapeutics, Inc. Common Stock | -188.19 Million USD | 92.687% |
| Pyxis Oncology, Inc. | -82.19 Million USD | 83.257% |
| XTL Biopharmaceuticals Ltd. | -765 Thousand USD | -1698.954% |
| Virios Therapeutics, Inc. | -5.44 Million USD | -152.657% |
| OKYO Pharma Limited | -15.74 Thousand USD | -87279.276% |
| Savara Inc. | -60 Million USD | 77.066% |
| Windtree Therapeutics, Inc. | -17.53 Million USD | 21.535% |
| Curis, Inc. | -48.33 Million USD | 71.526% |
| Carmell Therapeutics Corporation | -5.21 Million USD | -163.777% |
| Achieve Life Sciences, Inc. | -27.25 Million USD | 49.497% |
| BeiGene, Ltd. | -1.2 Billion USD | 98.861% |
| Protagonist Therapeutics, Inc. | -93.65 Million USD | 85.305% |
| Erasca, Inc. | -141.52 Million USD | 90.276% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -204.0% |
| Protagenic Therapeutics, Inc. | -4.52 Million USD | -204.0% |
| Vincerx Pharma, Inc. | -42.6 Million USD | 67.702% |
| Fresh Tracks Therapeutics, Inc. | -6.36 Million USD | -116.384% |
| Acrivon Therapeutics, Inc. Common Stock | -67.23 Million USD | 79.532% |
| Celldex Therapeutics, Inc. | -154.54 Million USD | 91.095% |
| Cogent Biosciences, Inc. | -208.13 Million USD | 93.388% |
| Adicet Bio, Inc. | -152.03 Million USD | 90.948% |
| Amicus Therapeutics, Inc. | -73.49 Million USD | 81.275% |
| Aditxt, Inc. | -26.06 Million USD | 47.196% |
| Adagene Inc. | -23.71 Million USD | 41.981% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -88.26% |
| Quantum-Si incorporated | -111.17 Million USD | 87.621% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 5.596% |
| Voyager Therapeutics, Inc. | 122.01 Million USD | 111.279% |
| Compugen Ltd. | -12.99 Million USD | -5.927% |
| Generation Bio Co. | -138.56 Million USD | 90.068% |
| Astria Therapeutics, Inc. | -83.03 Million USD | 83.425% |
| Black Diamond Therapeutics, Inc. | -86.46 Million USD | 84.083% |
| Invivyd, Inc. | -207.78 Million USD | 93.377% |
| Relay Therapeutics, Inc. | -373 Million USD | 96.31% |
| Quoin Pharmaceuticals, Ltd. | -9.37 Million USD | -46.74% |
| Spero Therapeutics, Inc. | 21.48 Million USD | 164.066% |
| Artelo Biosciences, Inc. | -10.28 Million USD | -33.78% |
| 2seventy bio, Inc. | -216.7 Million USD | 93.649% |
| Instil Bio, Inc. | -159.16 Million USD | 91.354% |
| Capricor Therapeutics, Inc. | -24.07 Million USD | 42.844% |
| Elevai Labs, Inc. Common Stock | -3.66 Million USD | -275.081% |
| GeoVax Labs, Inc. | -26.74 Million USD | 48.54% |
| Citius Pharmaceuticals, Inc. | -36.73 Million USD | 62.534% |
| Relmada Therapeutics, Inc. | -103.7 Million USD | 86.729% |
| ALX Oncology Holdings Inc. | -170.27 Million USD | 91.918% |
| Vir Biotechnology, Inc. | -684.3 Million USD | 97.989% |
| Evaxion Biotech A/S | -22.19 Million USD | 38.001% |
| Ocular Therapeutix, Inc. | -82.38 Million USD | 83.295% |
| Verve Therapeutics, Inc. | -223.12 Million USD | 93.832% |
| Tyra Biosciences, Inc. | -79.94 Million USD | 82.786% |
| Cingulate Inc. | -22.75 Million USD | 39.532% |
| Galmed Pharmaceuticals Ltd. | 7.49 Million USD | 283.689% |
| Unity Biotechnology, Inc. | -44.66 Million USD | 69.19% |
| Connect Biopharma Holdings Limited | -62.07 Million USD | 77.83% |
| Clearmind Medicine Inc. | -8.74 Million USD | -57.436% |
| Bolt Biotherapeutics, Inc. | -76.19 Million USD | 81.939% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -369.215% |
| Viking Therapeutics, Inc. | -100.82 Million USD | 86.351% |
| Madrigal Pharmaceuticals, Inc. | -380.49 Million USD | 96.383% |
| ImmunityBio, Inc. | -362.25 Million USD | 96.201% |
| Korro Bio, Inc. | -84.53 Million USD | 83.72% |
| Kineta, Inc. | -15.72 Million USD | 12.472% |
| BioVie Inc. | -32.17 Million USD | 57.234% |
| Codexis, Inc. | -68.06 Million USD | 79.782% |
| Celularity Inc. | -192.28 Million USD | 92.843% |
| Aileron Therapeutics, Inc. | -16.27 Million USD | 15.446% |
| Crinetics Pharmaceuticals, Inc. | -222.6 Million USD | 93.818% |
| Virax Biolabs Group Limited | -6.49 Million USD | -111.838% |
| Cibus, Inc. | -318.88 Million USD | 95.684% |
| IN8bio, Inc. | -30.33 Million USD | 54.636% |
| Adverum Biotechnologies, Inc. | -123.79 Million USD | 88.883% |
| Avalo Therapeutics, Inc. | -23.44 Million USD | 41.298% |
| Ionis Pharmaceuticals, Inc. | -353.73 Million USD | 96.109% |
| Eyenovia, Inc. | -25.4 Million USD | 45.833% |
| Puma Biotechnology, Inc. | 32.64 Million USD | 142.163% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -147.429% |
| Elevation Oncology, Inc. | -45.44 Million USD | 69.717% |
| Xilio Therapeutics, Inc. | -79.13 Million USD | 82.609% |
| Cardiff Oncology, Inc. | -45.41 Million USD | 69.695% |
| Enanta Pharmaceuticals, Inc. | -137.2 Million USD | 89.97% |
| Regulus Therapeutics Inc. | -31.1 Million USD | 55.762% |
| Moolec Science SA | -6.65 Million USD | -106.829% |
| Acumen Pharmaceuticals, Inc. | -61.13 Million USD | 77.49% |
| LAVA Therapeutics N.V. | -43.25 Million USD | 68.183% |
| Atea Pharmaceuticals, Inc. | -164.16 Million USD | 91.617% |
| Compass Therapeutics, Inc. | -50.36 Million USD | 72.674% |
| Greenwich LifeSciences, Inc. | -9.32 Million USD | -47.536% |
| TFF Pharmaceuticals, Inc. | -21.89 Million USD | 37.144% |
| Humacyte, Inc. | -100.04 Million USD | 86.244% |
| PMV Pharmaceuticals, Inc. | -80.13 Million USD | 82.826% |
| Avenue Therapeutics, Inc. | -14.54 Million USD | 5.351% |
| Genelux Corporation | -24.16 Million USD | 43.05% |
| Trevi Therapeutics, Inc. | -33.92 Million USD | 59.432% |
| Notable Labs, Ltd. | -14.65 Million USD | 6.106% |
| Immunovant, Inc. | -282.7 Million USD | 95.132% |
| Quantum-Si incorporated | -111.17 Million USD | 87.621% |
| DiaMedica Therapeutics Inc. | -21.26 Million USD | 35.289% |
| Vera Therapeutics, Inc. | -102.01 Million USD | 86.509% |
| Acasti Pharma Inc. | -11.31 Million USD | -21.658% |
| MiNK Therapeutics, Inc. | -22.92 Million USD | 39.959% |
| Soleno Therapeutics, Inc. | -41.38 Million USD | 66.746% |
| PepGen Inc. | -84.76 Million USD | 83.765% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 39.896% |
| BriaCell Therapeutics Corp. | -32.8 Million USD | 58.053% |
| Immuneering Corporation | -58.41 Million USD | 76.44% |
| Lixte Biotechnology Holdings, Inc. | -5.09 Million USD | -170.361% |
| Belite Bio, Inc | -31.66 Million USD | 56.543% |
| XOMA Corporation | -41.84 Million USD | 67.114% |
| ARS Pharmaceuticals, Inc. | -67.52 Million USD | 79.618% |
| Bionomics Limited | -17.89 Billion USD | 99.923% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 138.571% |
| uniQure N.V. | -282.87 Million USD | 95.135% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -88.26% |
| Poseida Therapeutics, Inc. | -129.5 Million USD | 89.373% |
| Forte Biosciences, Inc. | -32.48 Million USD | 57.637% |
| Anebulo Pharmaceuticals, Inc. | -8.3 Million USD | -65.633% |
| Enlivex Therapeutics Ltd. | -29.39 Million USD | 53.183% |
| Conduit Pharmaceuticals Inc. | -5.56 Million USD | -147.429% |
| SeaStar Medical Holding Corporation | -14.21 Million USD | 3.153% |
| FibroBiologics, Inc. Common Stock | -8.88 Million USD | -54.821% |
| Altimmune, Inc. | -95.92 Million USD | 85.654% |
| LENZ Therapeutics, Inc. | -73.11 Million USD | 81.176% |
| Alpha Tau Medical Ltd. | 35.68 Million USD | 138.571% |
| Peak Bio, Inc. | -1356.23 USD | -1014624.641% |
| Zevra Therapeutics, Inc. | -49.6 Million USD | 72.256% |
| Benitec Biopharma Inc. | -22.49 Million USD | 38.808% |
| Spyre Therapeutics, Inc. | -242.3 Million USD | 94.32% |
| NKGen Biotech, Inc. Common Stock | -29.74 Million USD | 53.735% |
| Zura Bio Limited | -62.63 Million USD | 78.029% |
| PolyPid Ltd. | -22.86 Million USD | 39.817% |
| NKGen Biotech, Inc. Warrants | -29.74 Million USD | 53.735% |
| argenx SE | -425.04 Million USD | 96.762% |
| Immunome, Inc. | -109.53 Million USD | 87.435% |
| Verona Pharma plc | -67.83 Million USD | 79.711% |
| enGene Holdings Inc. Warrants | -26.06 Million USD | 47.191% |
| Shattuck Labs, Inc. | -91.95 Million USD | 85.034% |
| CervoMed Inc. | -7.81 Million USD | -76.145% |
| Plus Therapeutics, Inc. | -13.32 Million USD | -3.311% |
| Dianthus Therapeutics, Inc. | -48.17 Million USD | 71.433% |
| Moolec Science SA | -6.65 Million USD | -106.829% |
| Enveric Biosciences, Inc. | -16.44 Million USD | 16.332% |
| Design Therapeutics, Inc. | -78.19 Million USD | 82.399% |
| Leap Therapeutics, Inc. | -87.04 Million USD | 84.189% |
| Seelos Therapeutics, Inc. | -40.49 Million USD | 66.019% |
| Achilles Therapeutics plc | -75.25 Million USD | 81.713% |
| CERo Therapeutics Holdings, Inc. | -2.93 Million USD | -369.215% |
| CG Oncology, Inc. Common stock | -55.44 Million USD | 75.181% |
| Fractyl Health, Inc. Common Stock | -50.83 Million USD | 72.929% |
| Rani Therapeutics Holdings, Inc. | -66.09 Million USD | 79.18% |
| MoonLake Immunotherapeutics | -54.12 Million USD | 74.573% |
| Tourmaline Bio, Inc. | -45.4 Million USD | 69.693% |
| Beam Therapeutics Inc. | -176.48 Million USD | 92.202% |
| Mirum Pharmaceuticals, Inc. | -109.15 Million USD | 87.392% |
| AEON Biopharma, Inc. | -48.42 Million USD | 71.583% |
| Aadi Bioscience, Inc. | -71.93 Million USD | 80.868% |
| Enliven Therapeutics, Inc. | -83.52 Million USD | 83.524% |
| Kiora Pharmaceuticals, Inc. | -12.58 Million USD | -9.336% |
| NeurAxis, Inc. | -6.66 Million USD | -106.497% |
| Iovance Biotherapeutics, Inc. | -460.55 Million USD | 97.012% |
| Lumos Pharma, Inc. | -36.61 Million USD | 62.413% |
| Opiant Pharmaceuticals, Inc. | 5.15 Million USD | 366.896% |
| Palisade Bio, Inc. | -13.07 Million USD | -5.295% |
| Nutriband Inc. | -4.87 Million USD | -182.476% |
| Taysha Gene Therapies, Inc. | -72.43 Million USD | 81.002% |
| Neurogene Inc. | -55.58 Million USD | 75.241% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | -61.887% |
| CARGO Therapeutics, Inc. Common Stock | -96.71 Million USD | 85.77% |
| Athira Pharma, Inc. | -125.46 Million USD | 89.031% |
| HCW Biologics Inc. | -25.71 Million USD | 46.487% |
| XOMA Corporation | -41.84 Million USD | 67.114% |
| Nektar Therapeutics | -137.42 Million USD | 89.986% |
| Arvinas, Inc. | -401.5 Million USD | 96.572% |
| Tevogen Bio Holdings Inc. | -8843.03 USD | -155525.391% |
| Merus N.V. | -156.54 Million USD | 91.209% |
| Omega Therapeutics, Inc. | -100.26 Million USD | 86.274% |
| Quince Therapeutics, Inc. | -34.62 Million USD | 60.248% |
| Rezolute, Inc. | -70.42 Million USD | 80.458% |
| Clene Inc. | -40.54 Million USD | 66.053% |
| Indaptus Therapeutics, Inc. | -16.37 Million USD | 15.975% |
| BeyondSpring Inc. | -23.11 Million USD | 40.46% |
| Synlogic, Inc. | -55.16 Million USD | 75.051% |
| Allarity Therapeutics, Inc. | -17.92 Million USD | 23.242% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | -27.143% |
| Peak Bio, Inc. | -1356.23 USD | -1014624.641% |
| Werewolf Therapeutics, Inc. | -40.5 Million USD | 66.022% |
| Krystal Biotech, Inc. | -109.72 Million USD | 87.458% |
| Karyopharm Therapeutics Inc. | -129.53 Million USD | 89.376% |
| SpringWorks Therapeutics, Inc. | -343.01 Million USD | 95.988% |
| Lipella Pharmaceuticals Inc. | -4.74 Million USD | -189.973% |
| MannKind Corporation | 8.67 Million USD | 258.585% |
| Ikena Oncology, Inc. | -75.41 Million USD | 81.752% |
| Cyclerion Therapeutics, Inc. | -9.64 Million USD | -42.656% |
| Gyre Therapeutics, Inc. | -67.23 Million USD | 79.53% |
| Gossamer Bio, Inc. | -183.75 Million USD | 92.511% |
| CohBar, Inc. | -12.38 Million USD | -11.089% |
| Cognition Therapeutics, Inc. | -50.72 Million USD | 72.869% |
| NRx Pharmaceuticals, Inc. | -27.58 Million USD | 50.114% |
| Legend Biotech Corporation | -439.48 Million USD | 96.869% |
| Mural Oncology plc | -194.63 Million USD | 92.929% |
| Disc Medicine, Inc. | -91.12 Million USD | 84.898% |
| Champions Oncology, Inc. | -7.35 Million USD | -87.085% |
| REGENXBIO Inc. | -268.12 Million USD | 94.867% |
| Ensysce Biosciences, Inc. | -10.71 Million USD | -28.399% |
| Anavex Life Sciences Corp. | -55.75 Million USD | 75.317% |
| Cellectar Biosciences, Inc. | -38.96 Million USD | 64.677% |
| Edgewise Therapeutics, Inc. | -114.35 Million USD | 87.966% |
| Vaxart, Inc. | -83.34 Million USD | 83.488% |
| PharmaCyte Biotech, Inc. | -8.52 Million USD | -61.526% |
| Aldeyra Therapeutics, Inc. | -42.79 Million USD | 67.841% |
| Cellectis S.A. | -106.62 Million USD | 87.093% |
| Longeveron Inc. | -21.02 Million USD | 34.557% |
| Repare Therapeutics Inc. | -116.22 Million USD | 88.159% |
| Sarepta Therapeutics, Inc. | -267.82 Million USD | 94.862% |
| Inozyme Pharma, Inc. | -75.64 Million USD | 81.807% |
| Revolution Medicines, Inc. | -487.18 Million USD | 97.175% |
| Nymox Pharmaceutical Corporation | -6.65 Million USD | -106.885% |
| Third Harmonic Bio, Inc. | -43.95 Million USD | 68.69% |
| ArriVent BioPharma, Inc. Common Stock | -74.59 Million USD | 81.55% |
| AN2 Therapeutics, Inc. | -69.63 Million USD | 80.237% |
| Anixa Biosciences, Inc. | -11.01 Million USD | -24.984% |
| Vertex Pharmaceuticals Incorporated | 4.3 Billion USD | 100.319% |
| Denali Therapeutics Inc. | -196.69 Million USD | 93.004% |
| Revelation Biosciences, Inc. | -8.65 Million USD | -58.976% |
| Veru Inc. | -93.78 Million USD | 85.326% |
| Corvus Pharmaceuticals, Inc. | -23.32 Million USD | 41.009% |
| Cingulate Inc. | -22.75 Million USD | 39.532% |
| Passage Bio, Inc. | -108.38 Million USD | 87.303% |
| Context Therapeutics Inc. | -25.07 Million USD | 45.111% |
| Exicure, Inc. | -14.99 Million USD | 8.229% |
| Day One Biopharmaceuticals, Inc. | -206.06 Million USD | 93.321% |
| Oramed Pharmaceuticals Inc. | -40.59 Million USD | 66.102% |
| Scinai Immunotherapeutics Ltd. | -9.71 Million USD | -41.629% |
| Nuvalent, Inc. | -149.49 Million USD | 90.794% |
| ABVC BioPharma, Inc. | -8.21 Million USD | -67.492% |
| Carisma Therapeutics, Inc. | -88.73 Million USD | 84.49% |
| Unicycive Therapeutics, Inc. | -20.77 Million USD | 33.754% |
| OmniAb, Inc. | -69.41 Million USD | 80.175% |
| Anew Medical, Inc. | -1.3 Million USD | -957.932% |
| Fennec Pharmaceuticals Inc. | -12.77 Million USD | -7.76% |
| Lipocine Inc. | -17.93 Million USD | 23.25% |
| Lexeo Therapeutics, Inc. Common Stock | -68.51 Million USD | 79.913% |
| Nautilus Biotechnology, Inc. | -76.15 Million USD | 81.928% |
| SAB Biotherapeutics, Inc. | -38.07 Million USD | 63.856% |
| G1 Therapeutics, Inc. | -39.52 Million USD | 65.183% |
| Bellerophon Therapeutics, Inc. | -22.38 Million USD | 38.519% |
| Sage Therapeutics, Inc. | -579.84 Million USD | 97.627% |
| Ocugen, Inc. | -65.53 Million USD | 78.999% |
| Mind Medicine (MindMed) Inc. | -93.86 Million USD | 85.339% |
| Q32 Bio Inc. | -92.1 Million USD | 85.058% |
| Brainstorm Cell Therapeutics Inc. | -21.43 Million USD | 35.809% |
| Alumis Inc. Common Stock | -158.17 Million USD | 91.299% |
| Equillium, Inc. | -14.52 Million USD | 5.233% |
| Kyverna Therapeutics, Inc. | -62.4 Million USD | 77.948% |
| Coya Therapeutics, Inc. | -7.9 Million USD | -74.129% |
| CNS Pharmaceuticals, Inc. | -18.86 Million USD | 27.051% |
| Dominari Holdings Inc. | -21.79 Million USD | 36.86% |
| Edesa Biotech, Inc. | -9.22 Million USD | -49.218% |
| vTv Therapeutics Inc. | -25.5 Million USD | 46.036% |
| Bio-Techne Corporation | 206.68 Million USD | 106.658% |
| Agios Pharmaceuticals, Inc. | -391.48 Million USD | 96.485% |
| Harmony Biosciences Holdings, Inc. | 192.03 Million USD | 107.167% |
| Prelude Therapeutics Incorporated | -132.27 Million USD | 89.596% |
| Candel Therapeutics, Inc. | -38.39 Million USD | 64.153% |
| iTeos Therapeutics, Inc. | -151.1 Million USD | 90.892% |
| Nkarta, Inc. | -131.65 Million USD | 89.547% |
| BioCardia, Inc. | -11.64 Million USD | -18.19% |
| Iterum Therapeutics plc | -47.46 Million USD | 71.008% |